News

Viatris (NASDAQ: VTRS) could be on the verge of eating the lunch of Novo Nordisk's (NYSE: NVO) two golden cash cows: The diabetes drug Ozempic, and another version that's formulated for weight loss

Healthcare company Amgen (NASDAQ: AMGN) has been a reliable investment to own over what has been a turbulent year for the broader market. Its stock price is up 6.6% in that time, outpacing the 3.2%

When a company's revenue and earnings plunge, it's understandable if investors begin to worry about its dividend. Pfizer (NYSE: PFE) reported a 53% year-over-year decline in revenue in its latest

If you are looking for reliable dividend stocks that can provide steady income and growth in any market condition, you might want to consider these two blue chip companies that have proven their

High-yield dividend stocks often deliver better-than-average returns for investors over the long term, thanks to the power of compounding. Not all high-yield dividend stocks are table-pounding buys

Income investors won't be happy with dividends that aren't sustainable. Instead, they want to own dividend stocks that they can depend on.

Three Motley Fool contributors identified stocks that

Shares of Sage Therapeutics (NASDAQ: SAGE) were down by more than 40% for the week at 11 a.m. on Friday, according to data provided by S&P Global Market Intelligence. The pharmaceutical company's

Investing becomes an easier process the moment that you shift from a trading mindset to an ownership approach. That transformation begins when you realize that behind every stock ticker, there's a

Dividend stocks can be great additions to anyone's portfolio, and it's even better to buy quality ones when they're down. While the market has roared back this year following a downturn in 2022, it

Viatris (NASDAQ: VTRS) spun off from Pfizer and merged with Mylan back in 2020. It's a generic drugmaker with a diverse, global business that serves patients and customers in over 165 countries and

Abbott Laboratories (NYSE: ABT) posted its latest earnings numbers last month, and there's reason to be optimistic about the business. Although a drop in COVID testing means sales are down overall

Biogen (NASDAQ: BIIB) is an intriguing stock right now. Its business has struggled to generate growth in recent years, but some recent catalysts could turn things around. For starters, the company's

Biotech company Vertex Pharmaceuticals (NASDAQ: VRTX) has made for a solid investment over the past decade, more than quadrupling in value during that period. The stock generated fantastic returns

The cost of living is getting more and more expensive. This is because inflation steadily diminishes the value of the U.S. dollar over time, and the purchasing power of said dollar as a result.

One

If you look at the S&P 500, which is up more than 18% this year, or the Nasdaq Composite, which is up more than 34% in 2023, it appears the markets are booming. If you look specifically at biotech

If you're looking for stocks that can deliver better-than-average returns in the long run, you might want to consider these two biotechs: Exact Sciences (NASDAQ: EXAS) and Vertex Pharmaceuticals

GDP grew at a rate of 2.4% in the second quarter as the economy did better than expected. And many businesses are also seeing strong demand for their products and services. That, in turn, leads to

Alzheimer's patients could soon have more treatment options available. Biogen's Leqembi obtained approval from the U.S. Food and Drug Administration earlier this year, and another treatment from Eli

Pfizer (NYSE: PFE) provides investors with an attractive dividend that currently yields 4.7%. To collect $1,000 in annual dividends at that rate, you would need to invest approximately $21,300

Viatris (NASDAQ: VTRS) is a stock of immense interest among the dividend investing community, and it's no surprise why. Generic drugmakers, when operating smoothly, can be veritable cash machines

Biotech giant Biogen (NASDAQ: BIIB) can't seem to keep its name out of the news. After a recent major approval for its Alzheimer's disease (AD) medicine Leqembi, the company just announced that it

As one of the hottest and most-watched companies in the biopharmaceutical sector, Vertex Pharmaceuticals (NASDAQ: VRTX) has a unique mix of stability and growth potential that's attractive to a

Image source: The Motley Fool.

Zoetis (NYSE: ZTS)Q2 2023 Earnings CallAug 08, 2023, 8:30 a.m. ET

Operator

Continue reading

Source Fool.com

Monday was a dark day for Sage Therapeutics (NASDAQ: SAGE), a company that focuses on developing therapies for brain disorders. The stock plummeted by more than 53% after the company revealed that

How do you know when a former favorite dividend stock is no longer one you should buy, or hold? Some would say it's time to look away as soon as the profits the company uses to make dividend